ReviewFrontiers in neurology2017
The Role of T1-Weighted Derived Measures of Neurodegeneration for Assessing Disability Progression in Multiple Sclerosis.
Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Neuroimaging markers and disability scales in multiple sclerosis: A systematic review and meta-analysis.PloS one · 2024Pooled it
- A Critical Systematic Review of Current Evidence on the Effects of Physical Exercise on Whole/Regional Grey Matter Brain Volume in Populations at Risk of Neurodegeneration.Sports medicine (Auckland, N.Z.) · 2021Pooled it
- Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Trial
- FreeSurfer-Based MRI Volumetry Reveals Thalamic and Hippocampal Atrophy as Significant Correlates of Disability in Multiple Sclerosis.Medicina (Kaunas, Lithuania) · 2026Article
- Cross-sectional brain volumetric measures and disability outcomes in relapsing-remitting multiple sclerosis.Journal of neurology · 2026Observational
- High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.Annals of neurology · 2025Article
- Current Clinical Applications of Structural MRI in Neurological Disorders.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Trajectories of self-reported fatigue following initiation of multiple sclerosis disease-modifying therapy.Journal of neurology, neurosurgery, and psychiatry · 2024Observational
- Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.Journal of neurology · 2024Observational
- Sensitive Identification of Asymmetries and Neuromuscular Deficits in Lower Limb Function in Early Multiple Sclerosis.Neurorehabilitation and neural repair · 2024Article
- Clinical variables influencing the perception of fatigue in people with multiple sclerosis: a cross-sectional study using FSIQ-RMS.BMC neurology · 2024Article
- T1 hypointense brain lesions in NMOSD and its relevance with disability: a single institution cross-sectional study.BMC neurology · 2024Article
- Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?Therapeutic advances in neurological disorders · 2024Review
- Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.Journal of neurology · 2022Observational
- Histological analysis of sleep and circadian brain circuitry in cranial radiation-induced hypersomnolence (C-RIH) mouse model.Scientific reports · 2022Article
- Automatic deep learning multicontrast corpus callosum segmentation in multiple sclerosis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2022Article
- Predictive MRI Biomarkers in MS-A Critical Review.Medicina (Kaunas, Lithuania) · 2022Review
- Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.Annals of neurology · 2022Observational
- Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide.Frontiers in immunology · 2022Review
- Rationale and design of the brain magnetic resonance imaging protocol for FutureMS: a longitudinal multi-centre study of newly diagnosed patients with relapsing-remitting multiple sclerosis in Scotland.Wellcome open research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMultiple sclerosis (MS) is characterised by the accumulation of permanent neurological disability secondary to irreversible tissue loss (neurodegeneration) in the brain and spinal cord. MRI measures derived from T1-weighted image analysis (i.e., black holes and atrophy) are correlated with pathological measures of irreversible tissue loss. Quantifying the degree of neurodegeneration
methodsA systematic PubMed search was conducted in January 2017 to identify MRI studies in MS patients investigating the relationship between "black holes" and/or atrophy in the brain and spinal cord, and disability. Results were limited to human studies published in English in the previous 10 years.
resultsA large number of studies have evaluated the association between the previous MRI measures and disability. These vary considerably in terms of study design, duration of follow-up, size, and phenotype of the patient population. Most, although not all, have shown that there is a significant correlation between disability and black holes in the brain, as well as atrophy of the whole brain and grey matter. The results for brain white matter atrophy are less consistently positive, whereas studies evaluating spinal cord atrophy consistently showed a significant correlation with disability. Newer ways of measuring atrophy, thanks to the development of segmentation and voxel-wise methods, have allowed us to assess the involvement of strategic regions of the CNS (e.g., thalamus) and to map the regional distribution of damage. This has resulted in better correlations between MRI measures and disability and in the identification of the critical role played by some CNS structures for MS clinical manifestations.
conclusionThe evaluation of MRI measures of atrophy as predictive markers of disability in MS is a highly active area of research. At present, measurement of atrophy remains within the realm of clinical studies, but its utility in clinical practice has been recognized and barriers to its implementation are starting to be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.